黛力新联合泮托拉唑治疗合并焦虑抑郁的上腹痛综合征的临床研究

摘要
图/表
参考文献(21)
相关文章 (9)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨黛力新联合泮托拉唑治疗合并焦虑抑郁的上腹痛综合征（EPS）的效果。方法将我院2012年3月～2016年7月172例合并焦虑抑郁的EPS患者采用随机数字分配法分为两组，其中治疗组（n=86）口服黛力新及泮托拉唑，对照组（n=86）仅口服泮托拉唑，疗程均为4周。观察两组患者上腹部烧灼感及上腹部疼痛等症状改善程度。结果治疗4周后，治疗组HADs评分治疗后均比治疗前显著下降（P＜0.01），对照组HADs评分治疗后较治疗前都有所下降，但差异无统计学意义（P＞0.05）。治疗后，两组HADs评分比较，差异有统计学意义（P＜0.01）；治疗组EPS症状总评分下降幅度显著大于对照组（P＜0.01）。治疗组总有效率为83.7%，显著高于对照组的46.5%，差异有统计学意义（P＜0.01）。治疗后，治疗组药物起效时间为（4.2±0.8）d，对照组为（5.9±1.5）d，差异有统计学意义（P＜0.01）。结论黛力新联合泮托拉唑治疗合并焦虑抑郁的EPS，可明显提高其临床效果，不良反应轻微，具有重要的临床意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	薛建波
	仝建军
	马丽
	徐涛

关键词 ：氟哌噻吨美利曲辛片, 泮托拉唑, 上腹痛综合征, 焦虑抑郁

Abstract：Objective To explore efficacy of Deanxit(Melitracen and flupentixol)combined with Pantoprazole in the treatment of epigastric pain syndrome(EPS)combined with anxiety and depression.Methods 172 patients with EPS combined with anxiety and depression in our hospital from March 2012 to July 2016 were randomly divided into two groups by random digital distribution method,patients in treatment group(n=86)received Deanxit plus Pantoprazole orally,and control group(n=86)received Pantoprazole orally.The course of treatment was 4 weeks.The symptoms,such as repeated epigastric burning and epigastric pain were evaluated.Results After treatment for 4 weeks,scores of HADs in treatment group was lower than that before treatment(P＜0.01),however,there was no difference in control group(P＞0.05).After treatment,the difference was statistically significant in HADs score between two groups(P＜0.01);EPS symptom score in the treatment group was significantly greater than that in the control group(P＜0.01).There was a significant difference in total effectiveness rate between two groups(83.7%vs.46.5%,P＜0.01).After treatment,onset time of the treatment group was(4.2±0.8)d,with(5.9±1.5)d in the control group,and the difference was statistically significant (P＜0.01).Conclusion Deanxit has a satisfactory efficacy and slight adverse reactions in the treatment of epigastric pain syndrome with symptoms of anxiety and depression,which has an important clinical significance.

Key words： Melitracen and flupentixol Pantoprazole Epigastric pain syndrome Anxiety and depression

作者简介: 薛建波（1979-），男，汉族，河北邢台人，硕士，主治医师，研究方向：功能性胃肠病的诊治

引用本文:

薛建波；仝建军；马丽；徐涛. 黛力新联合泮托拉唑治疗合并焦虑抑郁的上腹痛综合征的临床研究[J]. 中国当代医药, 2017, 24(1): 55-58.
XUE Jian-bo；TONG Jian-jun；MA Li；XU Tao. Clinical study of Deanxit combined with Pantoprazole in the treatment of abdominal pain syndrome combined with anxiety and depression. 中国当代医药, 2017, 24(1): 55-58.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I1/55

[1]	Tack J，Talley NJ，Camilleri M，et al.Functional gastroduodenal disorders[J].Gastroenterology，2006，130（5）：1466-1479.
[2]	罗马委员会.功能性胃肠病罗马Ⅲ诊断标准[J].胃肠病学，2006，11（12）：761-762.
[3]	Koloski NA，Jones M，Talley NJ.Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia：a 1-year population-based prospective study[J].Aliment Pharmacol Ther，2016，44（6）：592-600.
[4]	赵威，张莉莉，邓宝茹.氟哌噻吨美利曲辛联合质子泵抑制剂治疗上腹痛综合征的疗效观察[J].胃肠病学，2014，19（2）：89-92.
[5]	Zigmond AS，Snaith RP.The hospital anxiety and depression scale[J].Acta Psychiatr Scand，1983，67（6）：361-370.
[6]	Karling P，Maripuu M，Wikgren M，et al.Association be-tween gastrointestinal symptoms and affectivity in patients with bipolar disorder[J].World J Gastroenterol，2016，22（38）：8540-8548.
[7]	颜文娟，李蜀豫.便秘型肠易激综合征患者直肠肛管压力的改变与焦虑/抑郁情绪测定评分的临床意义[J].临床消化病杂志，2016，26（4）：230-232.
[8]	Shinozaki S，Osawa H，Sakamoto H，et al.The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia[J].J Med Invest，2016，63（3-4）：230-235.
[12]	陈玉龙.慢性胃肠疾病的心身医学观[J].中华诊断学电子杂志，2016，4（3）：168-172.
[13]	朱丽明，洪霞，方秀才，等.功能性消化不良与精神心理障碍共病的临床研究[J].中华内科杂志，2015，54（6）：525-529.
[14]	BranR，KuoB.Functionaldyspepsia[J].TherapAdv Gastroenterol，2010，3（3）：145-164.
[17]	陈玉龙.慢性胃炎与功能性消化不良诊治的心身医学观[J].中华消化杂志，2015，35（9）：577-579.
[9]	Hsu YC，Liou JM，Yang TH，et al.Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia：is therapeutic response predicted by RomeⅢsubgroups?[J].J Gastroenterol，2011，46（2）：183-190.
[10]	Van Oudenhove L，Törnblom H，Störsrud S，et al.Depression and Somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome[J].Gastroenterology，2016，150（4）：866-874.
[11]	Dibaise JK，Islam RS，Dueck AC，et al.Psychological distress in RomeⅢfunctional dyspepsia patients presenting for testing of gastric emptying[J].Neurogastroenterol Motil，2016，28（2）：196-205.
[15]	Jang SH，Ryu HS，Choi SC，et al.Psychological factors influence the overlap syndrome in functional gastrointestinal disorders and their effect on quality of life among firefighters in South Korea[J].J Dig Dis，2016，17（4）：236-243.
[16]	Levy RL，Olden KW，Nalibof BD，et al.Psychosocial aspects of the functional gastrointestinal disorders[J].Gastroenterology，2006，130（5）：1447-1458.
[18]	李佩武，黄凯涛，高俊泽.雷贝拉唑联合多虑平治疗上腹痛综合征[J].现代消化及介入诊疗，2010，15（6）：350-352.
[19]	Hashash JG，Abdul-Baki H，Azar C，et al.Clinical trial：a randomized controlled cross-over study of flupenthixol+ melitracen in functional dyspepsia[J].Aliment Pharmacol Ther，2008，27（11）：1148-1155.
[20]	Yan XJ，Li WT，Chen X，et al.Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients[J].World J Gastroenterol，2015，21（15）：4652-4659.
[21]	廖国建.氟哌噻吨美利曲辛联合质子泵抑制剂对上腹痛综合征患者的影响[J].胃肠病学，2015，20（8）；489-492.